Importance Patterns-of-failure studies suggest that in metastatic non–small-cell lung cancer (NSCLC)
sites of gross disease at presentation are the first to progress when treated with …

… phase II clinical trial of sorafenib in combination with erlotinib for the treatment of patients
with non–small-cell lung cancer using change in tumor … the sample size of the trial, we made …

… The Lung Cancer Study Group investigated the value of postoperative therapy in such … of
stage II and stage IIIa non–small-cell lung cancer, we conducted a randomized trial comparing …

… shown preliminary activity in non–small-cell lung cancer (NSCLC). Patients with advanced
NSCLC were treated with erlotinib with or without sorafenib in this multicenter phase II trial. …

… phase II overall antitumor response rates of 18% to 22% in patients treated with these drugs
as initial therapy for inoperable NSCLC.19.In this trial… Two additional reports of phase II trials …

… The phase I portion of our phase I/II clinical trial of gefitinib and everolimus was reported …
of the phase II portion of this trial are reported in this study. The objective of the phase II portion …

… The trial was designed as a prospective phase II trial. The primary goal of the study was to …
in months between the day of surgical resection of lung cancer and the date of death from any …

… (39 patients in stage 1 of the study and an additional 21 patients in stage 2) were … two
confirmed objective responses were needed in stage 1 to allow expansion of the trial to stage 2…

… , two doses (250 and 500 mg/d) were selected for investigation in phase II and phase III trials…
The 250 mg/d dose is higher than the lowest dose level at which objective tumor regression …

Purpose To determine the efficacy of cetuximab in patients with recurrent or progressive non–small-cell
lung cancer (NSCLC) after receiving at least one prior chemotherapy regimen. …